AbbVie (ABBV.US) expands Oxford UK R&D facility, betting on drug innovation in immunology, neuroscience, and oncology

智通财经2026/11/04 02:50

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

According to reports from Zhitong Finance APP, American pharmaceutical company AbbVie (ABBV.US) announced on Wednesday that, as part of an investment plan exceeding £120 million (approximately $161 million), it has expanded its research and development facilities in Oxford, UK. This investment comes a few months after the US and the UK finalized an agreement aimed at raising UK drug prices based on the latest US drug pricing policies proposed by President Trump.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AbbVie (ABBV.US) expands Oxford UK R&D facility, betting on drug innovation in immunology, neuroscience, and oncology

You may also like

Crypto prices